Incidentaloma secondary prevention

Revision as of 23:54, 29 August 2017 by Medhat (talk | contribs)
Jump to navigation Jump to search

Incidentaloma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Incidentaloma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Incidentaloma secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Incidentaloma secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Incidentaloma secondary prevention

CDC on Incidentaloma secondary prevention

Incidentaloma secondary prevention in the news

Blogs on Incidentaloma secondary prevention

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Incidentaloma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

  • Effective measures for the secondary prevention of [disease name] include:
  • Excess hormone secretion may develop in up to 20% of patients with previously nonfunctional adrenal tumors during follow- up (37, 38, 123).
  • The transformation rate of nonfunctional adrenal masses to functional tumors seems to be higher in adrenal masses greater than 3 cm in size (38).
  • Annual biochemical follow-up for up to 5 yr may be reasonable for patients with adrenal incidentalomas, especially if the tumor is more than 3 cmin size (20, 21, 37, 45).
  • No routine follow-up of adrenal incidentalomas with a non-contrast attenuation value no greater than 10 HU.
  • A one-time follow-up scan in 6–12 months may be reassuring to the physician and the patient (2, 12, 40, 124).
  • Patients with adrenal masses less than 4 cm in size and a non-contrast attenuation value more than 10 HU should have a repeat CT study in 3–6 months and then yearly for 2 yr.
  • Surgical excision may be considered for tumors with indeterminate radiological features that grow at least 0.8 cm over 3- to 12-month follow-up (10).

References

Template:WH Template:WS